Case Report
Copyright ©The Author(s) 2024.
World J Clin Cases. Jan 6, 2024; 12(1): 136-141
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.136
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Skin lesion characteristics in patient with blastic plasmacytoid dendritic cell neoplasm. A: On admission for physical examination Breakdown of subcutaneous nodules on the head; B: Abdominal skin nodule; C: Skin nodules on back; D-F: In February 2021, skin healing was induced by idarubicin combined with cytarabine (IA) regimen combined with high-dose cytarabine regimen for a total of three cycles.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Abdominal skin tumor cells diffusely positive for CD7, CD56, CD23, Ki-67 (hematoxylin and eosin, 400 ×).
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 The treatment process and efficacy evaluation of patient with blastic plasmacytoid dendritic cell neoplasm. allo-HSCT: Allogeneic hematopoietic stem cell transplantation; AZA: Azacitidine; MTX: Methotrexate; IDA: Idarubicin; Ara-C: Cytarabine; CC: Complete donor chimerism; DC: Donor chimerism; MRD: Minimal residual disease; EBV: Epstein–Barr virus; CMV: Cytomegalovirus; PET-CT: Positron emission tomography–computed tomography.